VistaGen Therapeutics, Inc.

The usual pattern of reporting positive clinical trial results or winning US Food and Drug Administration approval then launching a large follow-on public offering (FOPO) has become less common under

Veru Inc. started out focused mainly on cancer supportive therapy, but now thinks it has identified a new direction for its lead candidate, the selective androgen receptor modulator (SARM) enobosarm,

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Hasten Gets Greater China Rights T

VistaGen Therapeutics, Inc. suffered a significant setback last year when its lead drug candidate fasedienol (PH94B) for treatment of social anxiety disorder failed to meet the primary endpoint in th